Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A) (CCM) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, CCM carries an RQD Score of 22 out of 100, a letter grade of E, and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 2 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 5 of 20 (institutional accumulation and options positioning), Insider Conviction scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 7 of 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 5 of 20 (Altman Z 0.2; Piotroski F 2/9; Debt/Equity 0.5). For a prospective investor, the implication is that the rating's weakest elements are cash generation, balance-sheet forensics, and insider and institutional signals, leaving limited upside drivers in the source data. The valuation tradeoff is that a $15.9M market capitalization against reported FY 2025 debt of $352.6M sits in a capital structure where equity appears small relative to obligations, which the source data flags as elevated forensic risk. The rating therefore frames CCM as a high-risk situation where the downside drivers are more visible in the data than any upside catalyst.

Per the market data, the gross margin is 5.7%, the operating margin is -57.6%, and the net margin is -20.4%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 2 of 9, both in the distressed range the rating reflects. The Debt/Equity ratio is 0.5 per the Forensic Balance Sheet pillar. Revenue declined from $73.3M in FY 2023 to $51.3M in FY 2024 before recovering to $65.0M in FY 2025, while operating losses persisted across all three periods.

• What are the company's specific products, service lines, and customer base, given that the source data provides only sector and industry classification?
• What is the composition and maturity of the $352.6M in reported FY 2025 debt, and how does it compare with the $42.6M in cash?
• Why are EPS, P/E, forward P/E, and EV/EBITDA unavailable, and what would those metrics show about valuation?
• What drove the 2024 revenue decline and the 2025 recovery, and are operating losses expected to narrow?
• What does the FY 2023 cash and debt position look like, given that those fields are unreported in the source data?